BACKGROUND: The rs58542926 polymorphism in transmembrane 6 superfamily member 2 (TM6SF2) is a genetic factor predisposing to nonalcoholic fatty liver disease. We aimed to explore the effect of recipient and donor TM6SF2 rs58542926 genotypes on liver graft fat content after liver transplantation. METHODS: Steatosis was evaluated in liver biopsies from 268 adult recipients. The influence of recipient and donor TM6SF2 genotypes, patatin-like phospholipase domain-containing 3 (PNPLA3) rs738409 genotypes, and nongenetic factors on the steatosis grade assessed 6-30 months after transplantation was analyzed by ordinal logistic regression. RESULTS: The presence of the TM6SF2 c.499A allele in the donor (P = 0.014), PNPLA3 c.444G allele in the donor (P < 0.001), posttransplant body mass index (P < 0.001), and serum triglycerides (P = 0.047) independently predicted increased liver fat content on multivariable analysis, whereas noncirrhotic liver disease, as an indication for liver transplantation, was associated with lower risk of steatosis (P = 0.003). The effects of the donor TM6SF2 A and PNPLA3 G alleles were additive, with an odds ratio of 4.90 (95% confidence interval, 2.01-13.00; P < 0.001), when both minor alleles were present compared with an odds ratio of 2.22 (95% confidence interval, 1.42-3.61; P = 0.002) when only one of these alleles was present. CONCLUSIONS: The donor TM6SF2 c.499A allele is an independent risk factor of liver graft steatosis after liver transplantation that is additive to the effects of donor PNPLA3 c.444G allele.

Center for Experimental Medicine Institute for Clinical and Experimental Medicine Prague Czech Republic

Department of Clinical and Transplant Pathology Institute for Clinical and Experimental Medicine Prague Czech Republic

Department of Hepatogastroenterology Institute for Clinical and Experimental Medicine Prague Czech Republic

Medical Statistics Unit Institute for Clinical and Experimental Medicine Prague Czech Republic

Zobrazit více v PubMed

Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity.Hepatology2004401387–1395

Bedogni G, Miglioli L, Masutti F, et al. Prevalence of and risk factors for nonalcoholic fatty liver disease: the dionysos nutrition and liver study.Hepatology20054244–52

Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study.Gastroenterology2005129113–121

Söderberg C, Stål P, Askling J, et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up.Hepatology201051595–602

Calori G, Lattuada G, Ragogna F, et al. Fatty liver index and mortality: the Cremona study in the 15th year of follow-up.Hepatology201154145–152

Anstee QM, Seth D, Day CP. Genetic factors that affect risk of alcoholic and nonalcoholic fatty liver disease.Gastroenterology20161501728–1744.e7

Eslam M, Valenti L, Romeo S. Genetics and epigenetics of NAFLD and NASH: clinical impact.J Hepatol201868268–279

Schwimmer JB, Celedon MA, Lavine JE, et al. Heritability of nonalcoholic fatty liver disease.Gastroenterology20091361585–1592

Loomba R, Schork N, Chen CH, et al.; Genetics of NAFLD in Twins ConsortiumHeritability of hepatic fibrosis and steatosis based on a prospective twin study.Gastroenterology20151491784–1793

Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease.Nat Genet2008401461–1465

Stender S, Kozlitina J, Nordestgaard BG, et al. Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci.Nat Genet201749842–847

Rotman Y, Koh C, Zmuda JM, et al.; NASH CRNThe association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease.Hepatology201052894–903

Speliotes EK, Butler JL, Palmer CD, et al.; GIANT Consortium; MIGen Consortium; NASH CRNPNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease.Hepatology201052904–912

Valenti L, Al-Serri A, Daly AK, et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease.Hepatology2010511209–1217

Zhang S, Wu H, Wu X, et al. Association between PNPLA3 rs738409 polymorphisms and risk of hepatocellular carcinoma and its development in patients with cirrhosis: a meta-analysis.Int J Clin Exp Med201586638–6649

Finkenstedt A, Auer C, Glodny B, et al. Patatin-like phospholipase domain-containing protein 3 rs738409-G in recipients of liver transplants is a risk factor for graft steatosis.Clin Gastroenterol Hepatol2013111667–1672

Trunečka P, Míková I, Dlouhá D, et al. Donor PNPLA3 rs738409 genotype is a risk factor for graft steatosis. a post-transplant biopsy-based study.Dig Liver Dis201850490–495

Miyaaki H, Miuma S, Taura N, et al. PNPLA3 as a liver steatosis risk factor following living-donor liver transplantation for hepatitis C.Hepatol Res201848E335–E339

Kozlitina J, Smagris E, Stender S, et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease.Nat Genet201446352–356

Mahdessian H, Taxiarchis A, Popov S, et al. TM6SF2 is a regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid droplet content.Proc Natl Acad Sci U S A2014111248913–8918

O’Hare EA, Yang R, Yerges-Armstrong LM, et al. TM6SF2 rs58542926 impacts lipid processing in liver and small intestine.Hepatology2017651526–1542

Liu YL, Reeves HL, Burt AD, et al. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease.Nat Commun201454309

Dongiovanni P, Petta S, Maglio C, et al. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease.Hepatology201561506–514

Sookoian S, Castaño GO, Scian R, et al. Genetic variation in transmembrane 6 superfamily member 2 and the risk of nonalcoholic fatty liver disease and histological disease severity.Hepatology201561515–525

Krawczyk M, Rau M, Schattenberg JM, et al.; NAFLD Clinical Study GroupCombined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study.J Lipid Res201758247–255

Koo BK, Joo SK, Kim D, et al. Additive effects of PNPLA3 and TM6SF2 on the histological severity of non-alcoholic fatty liver disease.J Gastroenterol Hepatol2018331277–1285

Milano M, Aghemo A, Mancina RM, et al. Transmembrane 6 superfamily member 2 gene E167K variant impacts on steatosis and liver damage in chronic hepatitis C patients.Hepatology201562111–117

Coppola N, Rosa Z, Cirillo G, et al. TM6SF2 E167K variant is associated with severe steatosis in chronic hepatitis C, regardless of PNPLA3 polymorphism.Liver Int2015351959–1963

Manchiero C, Nunes AKDS, Magri MC, et al. The rs738409 polymorphism of the PNPLA3 gene is associated with hepatic steatosis and fibrosis in Brazilian patients with chronic hepatitis C.BMC Infect Dis201717780

Buch S, Stickel F, Trépo E, et al. A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis.Nat Genet2015471443–1448

Falleti E, Cussigh A, Cmet S, et al. PNPLA3 rs738409 and TM6SF2 rs58542926 variants increase the risk of hepatocellular carcinoma in alcoholic cirrhosis.Dig Liver Dis20164869–75

Stickel F, Buch S, Nischalke HD, et al. Genetic variants in PNPLA3 and TM6SF2 predispose to the development of hepatocellular carcinoma in individuals with alcohol-related cirrhosis.Am J Gastroenterol20181131475–1483

Raksayot M, Chuaypen N, Khlaiphuengsin A, et al. Independent and additive effects of PNPLA3 and TM6SF2 polymorphisms on the development of non-B, non-C hepatocellular carcinoma.J Gastroenterol201954427–436

Yalamanchili K, Saadeh S, Klintmalm GB, et al. Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease.Liver Transpl201016431–439

Dumortier J, Giostra E, Belbouab S, et al. Non-alcoholic fatty liver disease in liver transplant recipients: another story of “seed and soil”.Am J Gastroenterol2010105613–620

Dureja P, Mellinger J, Agni R, et al. NAFLD recurrence in liver transplant recipients.Transplantation201191684–689

Hejlova I, Honsova E, Sticova E, et al. Prevalence and risk factors of steatosis after liver transplantation and patient outcomes.Liver Transpl201622644–655

Narayanan P, Mara K, Izzy M, et al. Recurrent or de novo allograft steatosis and long-term outcomes after liver transplantation.Transplantation2019103e14–e21

Gitto S, de Maria N, di Benedetto F, et al. De-novo nonalcoholic steatohepatitis is associated with long-term increased mortality in liver transplant recipients.Eur J Gastroenterol Hepatol201830766–773

Idowu MO, Chhatrala R, Siddiqui MB, et al. De novo hepatic steatosis drives atherogenic risk in liver transplantation recipients.Liver Transpl2015211395–1402

Cífková R, Škodová Z, Bruthans J, et al. Longitudinal trends in major cardiovascular risk factors in the Czech population between 1985 and 2007/8. Czech MONICA and Czech post-MONICA.Atherosclerosis201011676–681

Kleiner DE, Brunt EM, Van Natta M, et al.; Nonalcoholic Steatohepatitis Clinical Research NetworkDesign and validation of a histological scoring system for nonalcoholic fatty liver disease.Hepatology2005411313–1321

Liu ZT, Chen TC, Lu XX, et al. PNPLA3 I148M variant affects non-alcoholic fatty liver disease in liver transplant recipients.World J Gastroenterol20152110054–10056

Smagris E, Gilyard S, BasuRay S, et al. Inactivation of TM6SF2, a gene defective in fatty liver disease, impairs lipidation but not secretion of very low density lipoproteins.J Biol Chem201629110659–10676

Li JZ, Huang Y, Karaman R, et al. Chronic overexpression of PNPLA3I148M in mouse liver causes hepatic steatosis.J Clin Invest20121224130–4144

Watt KD, Dierkhising R, Fan C, et al. Investigation of PNPLA3 and IL28B genotypes on diabetes and obesity after liver transplantation: insight into mechanisms of disease.Am J Transplant2013132450–2457

Kempinska-Podhorodecka A, Krawczyk M, Klak M, et al. Healthy PNPLA3 risk allele carriers present with unexpected body fat composition. A study of one thousand subjects.J Gastrointestin Liver Dis20142333–37

Wang X, Liu Z, Wang K, et al. Additive effects of the risk alleles of PNPLA3 and TM6SF2 on non-alcoholic fatty liver disease (NAFLD) in a Chinese population.Front Genet20167140

Chen L, Du S, Lu L, et al. The additive effects of the TM6SF2 E167K and PNPLA3 I148M polymorphisms on lipid metabolism.Oncotarget2017874209–74216

Petersen KF, Dufour S, Befroy D, et al. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes.Diabetes200554603–608

Machado MV, Cortez-Pinto H. Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal.J Hepatol2013581007–1019

Germani G, Laryea M, Rubbia-Brandt L, et al. Management of recurrent and de novo NAFLD/NASH after liver transplantation.Transplantation201910357–67

McCormack L, Petrowsky H, Jochum W, et al. Use of severely steatotic grafts in liver transplantation: a matched case-control study.Ann Surg2007246940–6discussion 946

Marsman WA, Wiesner RH, Rodriguez L, et al. Use of fatty donor liver is associated with diminished early patient and graft survival.Transplantation1996621246–1251

Li J, Liu B, Yan LN, et al. Reversal of graft steatosis after liver transplantation: prospective study.Transplant Proc2009413560–3563

Bhanji RA, Watt KD. Fatty allograft and cardiovascular outcomes after liver transplantation.Liver Transpl201723S76–S80

Serum miR-33a is associated with steatosis and inflammation in patients with non-alcoholic fatty liver disease after liver transplantation